HCG vs Gonadorelin: Which Protects Fertility on TRT?

When men start TRT, LH and FSH are suppressed within days to weeks as rising testosterone signals the hypothalamus and pituitary to reduce gonadotropin output. The result is testicular atrophy, impaired steroidogenesis, and near-complete suppression of spermatogenesis. Two pharmacological strategies attempt to maintain testicular function despite this suppression:

HCG (human chorionic gonadotropin) has been the standard approach for decades. It bypasses the suppressed pituitary entirely and binds LH/CG receptors directly on Leydig cells, maintaining intratesticular testosterone production and testicular volume. Its evidence base in TRT patients is extensive.

Gonadorelin (synthetic GnRH) is a newer, more physiologically elegant approach. Administered as twice-daily subcutaneous injections, it mimics the hypothalamic GnRH signal, stimulating the pituitary to release both LH and FSH in a near-physiological pulsatile pattern. This maintains the complete HPG cascade rather than bypassing it.

The fundamental difference is where in the axis each compound acts: HCG at the gonadal level, gonadorelin at the pituitary level (with downstream effects identical to endogenous signalling).

Level of action:

• HCG: Acts directly on testicular Leydig cells. The pituitary is completely bypassed. No LH or FSH is required from the pituitary for the effect to occur.
• Gonadorelin: Acts on anterior pituitary gonadotrophs. Requires the pituitary to be capable of responding. Stimulates both LH and FSH release, maintaining the full gonadotropin signal to the testes.

FSH stimulation:

• HCG: No FSH is stimulated. Sertoli cell function depends on whatever residual FSH exists from prior signalling. For men who have been on TRT for months to years, FSH is near zero and HCG alone cannot restore full spermatogenesis.
• Gonadorelin: Stimulates FSH alongside LH, maintaining Sertoli cell activity and the full spermatogenic support structure.

Estradiol impact:

• HCG: Significant estradiol elevation through intratesticular aromatase activation. At fertility-range doses, estradiol can rise to more than 4 times baseline within 24 hours of injection.
• Gonadorelin: More modest, proportionate estradiol rise. Does not cause the same degree of intratesticular aromatase stimulation. This is one of the practical advantages in men who are estradiol-sensitive.

Leydig cell desensitisation:

• HCG: Chronic high-dose HCG can downregulate LH/CG receptors on Leydig cells, reducing responsiveness over time. This is why dose minimisation (250 IU every other day rather than 1,500 IU three times weekly) is generally preferred for long-term use.
• Gonadorelin: Acts upstream at the pituitary; does not directly stimulate Leydig cell receptors and does not cause Leydig cell desensitisation.

Injection frequency:

• HCG: 2-3 injections per week.
• Gonadorelin: Twice daily injections. This is a significant practical barrier for many patients.

Choose HCG when:

• The patient is on active TRT and needs fertility preservation or testicular maintenance
• FSH recovery is not the primary concern (testicular volume and ITT maintenance is the goal)
• Injection frequency is a patient adherence concern (2-3x/week vs. twice daily for gonadorelin)
• There is a need for well-established clinical evidence specific to TRT patients
• Budget is a consideration (HCG is typically less expensive than gonadorelin)

Choose gonadorelin when:

• FSH stimulation is a priority (full spermatogenesis support)
• The patient is experiencing significant estradiol-related side effects from HCG and dose reduction has not resolved the problem
• Leydig cell desensitisation is a concern with long-term high-dose HCG use
• A more physiologically complete approach is preferred and the patient can manage twice-daily injections
• The prescriber has experience with gonadorelin protocols

Neither is appropriate when:

• The patient has primary hypogonadism (Leydig cell failure): neither gonadorelin nor HCG will stimulate adequate testosterone from damaged Leydig cells
• Exogenous androgens have been discontinued and HPTA restart is the goal: in this case, SERMs (enclomiphene or tamoxifen) are the appropriate first-line choice